This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ENDP.Q Overzicht aandelen
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Endo Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.0006 |
| 52 Week Hoogtepunt | US$0.08 |
| 52 Week Laag | US$0.000001 |
| Bèta | 0.80 |
| 11 maand verandering | 50.00% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -98.91% |
| 33 jaar verandering | -99.99% |
| 5 jaar verandering | -99.99% |
| Verandering sinds IPO | -100.00% |
Recent nieuws en updates
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Rendement voor aandeelhouders
| ENDP.Q | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0% | -3.7% | -1.6% |
| 1Y | -98.9% | 17.2% | 30.8% |
Rendement versus industrie: ENDP.Q underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Rendement versus markt: ENDP.Q underperformed the US Market which returned 22.8% over the past year.
Prijsvolatiliteit
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 207.3% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: ENDP.Q's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ENDP.Q's weekly volatility has increased from 125% to 207% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo Inc. Samenvatting
| ENDP.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$141.13k |
| Inkomsten(TTM) | -US$2.45b |
| Inkomsten(TTM) | US$2.01b |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs ENDP.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ENDP.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.01b |
| Kosten van inkomsten | US$941.90m |
| Brutowinst | US$1.07b |
| Overige uitgaven | US$3.52b |
| Inkomsten | -US$2.45b |
Laatst gerapporteerde inkomsten
Dec 31, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -10.41 |
| Brutomarge | 53.17% |
| Nettowinstmarge | -121.69% |
| Schuld/Eigen Vermogen Verhouding | -123.5% |
Hoe presteerde ENDP.Q op de lange termijn?
Bekijk historische prestaties en vergelijking